입자 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Particle Therapy Market size is expected to reach USD 3.88 Billion in 2034 from USD 2.02 Billion (2025) growing at a CAGR of 7.5% during 2026-2034.

The global particle therapy market is gaining momentum as advanced cancer treatment technologies become more widely adopted. Particle therapy, including proton and carbon ion therapy, is a highly precise radiation treatment used to target cancer cells while minimizing damage to surrounding healthy tissues. The growing prevalence of cancer and increasing demand for advanced oncology treatments are key factors driving market growth.

Technological advancements and the development of specialized cancer treatment centers are accelerating the adoption of particle therapy worldwide. Governments and healthcare institutions are investing in advanced radiation therapy infrastructure to improve cancer treatment outcomes. In addition, ongoing clinical research and improved treatment planning systems are enhancing the effectiveness and accessibility of particle therapy.

In the future, the particle therapy market is expected to expand as awareness of advanced cancer treatments increases globally. Continued research, technological innovation, and the establishment of new therapy centers will support market development. As healthcare systems focus on improving cancer survival rates and patient quality of life, particle therapy is likely to become an important component of modern oncology care.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy

• Proton Therapy
• Heavy lon

By Services

• Cyclotrons
• Synchrotrons
• Synchrocyclotrons

By Application

• Pediatric Cancer
• Lung Cancer
• Bladder Cancer
• Brain and Spinal Cord Tumors (BSCT)
• Breast Cancer
• Gastrointestinal (GI) Cancers
• Hepatocellular Carcinoma (HCC)
• Head and Neck Cancers (HNC)
• Others

By End-User

• Hospitals
• Academic & Research Centers

COMPANIES PROFILED

• Advanced Oncotherapy PLC, Danfysik AS, Hitachi, Ltd, IBA Worldwide, Mevion Medical Systems, Inc, Optivus Proton Therapy, Inc, Protom International, Inc, Provision Healthcare, Varian Medical Systems, Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PARTICLE THERAPY MARKET: BY THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy
• 4.2. Proton Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Heavy lon Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PARTICLE THERAPY MARKET: BY SERVICES 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Services
• 5.2. Cyclotrons Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Synchrotrons Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Synchrocyclotrons Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PARTICLE THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Pediatric Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Brain and Spinal Cord Tumors (BSCT) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Gastrointestinal (GI) Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Hepatocellular Carcinoma (HCC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Head and Neck Cancers (HNC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PARTICLE THERAPY MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic & Research Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PARTICLE THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapy
  • 8.2.2 By Services
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapy
  • 8.3.2 By Services
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapy
  • 8.4.2 By Services
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapy
  • 8.5.2 By Services
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapy
  • 8.6.2 By Services
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PARTICLE THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Advanced Oncotherapy PLC
  • 10.2.2 Danfysik A/S
  • 10.2.3 HitachiLtd
  • 10.2.4 IBA Worldwide
  • 10.2.5 Mevion Medical SystemsInc
  • 10.2.6 Optivus Proton TherapyInc
  • 10.2.7 Protom InternationalInc
  • 10.2.8 Provision Healthcare
  • 10.2.9 Varian Medical SystemsInc